About Us

DemeRx is a clinical stage pharmaceutical development company advancing noribogaine for alcohol use disorder.

Rising Star Award Winner

DemeRx-NB is advancing noribogaine in clinical trials to demonstrate its use as a safe and effective treatment for alcohol use disorder.


  • Alcohol and drug abuse “hijacks” the brain’s reward centers.  Painful cravings during early withdrawal drive an intractable cycle of relapse. 

  • Open label studies of ibogaine has demonstrated benefits in patients seeking to transition to sobriety.  Recent studies demonstrate that drug turns on neuroplasticity in addiction circuits of the brain.   These changes bring about a rapid “reset” which shuts off the blaring cravings and desire to use alcohol and drugs.

  • Noribogaine is an active metabolite of ibogaine and a potent neuroplastogen without the side effects of ibogaine.

  • DemeRx plans to develop a daily dose formulation of DMX-1001 (noribogaine) for the treatment of alcohol use disorder.

Bridging the research to clinical practice gap

Our Goal

We plan to advance oral dose formulations of noribogaine for patients in early recovery from alcohol use disorder to prevent relapse.

Result Driven

DemeRx will design clinical trials to  demonstrate that noribogaine provides a fast and lasting effect on alcohol craving, maintenance of abstinence or avoidance of heavy drinking in moderate to severe alcoholic patients who have sought treatment and successfully completed acute withdrawal.

Key Team

Deborah Mash
Pascal J. Goldschmidt

Key Team

Richard Serbin, Executive Chairman BoD

Global strategy advisor and entrepreneur with credentials both in pharmacy and law, 40 years of service as an FDA regulatory and patent attorney in the healthcare industry.

Deborah Mash, PhD Chief Executive Officer & Founder

Neuroscientist, inventor and entrepreneur with over 25 years of experience in the field of addiction biology and small molecule development.

Mark Ellison, PhD

Twenty years of experience in the pharmaceutical industry, clinical trial management, patient registries and FDA REMS monitoring.

Pascal J. Goldschmidt MD, FACC, FAHA, Chief Medical Officer

An accomplished physician (cardiologist), professor, healthcare leader, NIH-funded medical researcher and inventor.

John Thomas CPA, Chief Financial Officer

Decades of experience in senior management in biotech and healthcare fields.